Online ISSN: 2515-8260

Keywords : Ovarian Cancer


RECURRENT OVARIAN CANCER: MECHANISMS OF DEVELOPMENT OF PERITONEAL MALIGNANT ASCITES

Bunyod Saidkulov; Jurabek Abduraxmonov; Rahimov M. Nodir; Farkhod Raufov

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 2, Pages 2423-2428

Diagnostic approach and treatment of recurrent ovarian cancer has many
unresolved issues, the relevance of which is associated with late diagnosis and ultimately
low treatment effectiveness and high mortality rates. The clinical manifestation of
recurrent ovarian cancer is variable even within a morphologically similar group of
patients due to the high degree of heterogeneity of the tumor. Questions remain about how
wide the range of molecular genetic markers is and what is the correlation between their
level and the effectiveness of treatment for ovarian cancer recurrence. One of the most
promising ways to obtain information about the nature of the recurrence of the tumor
process in ovarian cancer (OC) can be the study of ascitic fluid (AF).

Advancement in Ovarian Cancer Treatment

Samta Gupta; Archana Mehta

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 6, Pages 832-838

Epithelial ovarian malignant growth is ordinarily analyzed at a propelled stage. The better current class of chemotherapy treatments result in the high frequency of full reductions, however, the repetition rate is also higher. The infection eventually is a cycle of free moments and repetitive scenes in most cases. Distinctive focused on treatment draws near and natural medications, as of now being worked on, bring the guarantee of transforming ovarian malignant growth into a sensible ceaseless ailment. In this survey, we examine the present standard in the treatment for ovarian malignancy, significant late examinations on the new variations of regular treatments, and new remedial methodologies, as of late endorsed as well as in clinical preliminaries. The following also have an opponent in angiogenic drugs, polyADP-ribose polymerase (PARP), developmental factor flagging inhibitors or folate receptor inhibitors. They also address the cost-effectiveness of certain new treatments and the question of best option for personalized therapy.